Biotech · Private company

Stemline Therapeutics, Inc.

Track this companyFree. Adds Stemline Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2516 recruiting or active

Pipeline programs30From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline30

AnastrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ElacestrantPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ExemestanePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
LetrozolePhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
TamoxifenPhase 3 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
AbemaciclibPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
AlpelisibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
AzacitidinePhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
BevacizumabPhase 2 · Adult Brain GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
CapivasertibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ElacestrantPhase 2 · Breast NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
ElacestrantPhase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
EverolimusPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
ImiquimodPhase 2 · Adult Brain GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
PalbociclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
RibociclibPhase 2 · Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
SL-401 7 µg/kg/dayPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
SL-401 9 µg/kg/dayPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
SL-701 + GM-CSFPhase 2 · Adult Brain GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)Phase 2 · Adult Brain GlioblastomaClinicalTrials.gov · fetched Nov 12, 2026
TagraxofuspPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
TagraxofuspPhase 2 · Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)ClinicalTrials.gov · fetched Nov 12, 2026
Tagraxofusp InjectionPhase 2 · MyelofibrosisClinicalTrials.gov · fetched Nov 12, 2026
Tagraxofusp-erzsPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
VenetoclaxPhase 2 · Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
ElacestrantPhase 1 · Advanced Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
Elacestrant dihydrochloridePhase 1 · Hepatic ImpairmentClinicalTrials.gov · fetched Nov 12, 2026
MEN2312Phase 1 · Advanced Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
MEN2501Phase 1 · Platinum-resistant Ovarian CancerClinicalTrials.gov · fetched Nov 12, 2026
SL-801Phase 1 · Solid TumorsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerPHASE2 · NOT_YET_RECRUITING · started Dec 18, 2026ClinicalTrials.gov NCT07634601 · fetched Nov 12, 2026
Ph 2 Elacestrant in ER Positive Uterine SarcomasPHASE2 · RECRUITING · started Mar 25, 2026ClinicalTrials.gov NCT07467772 · fetched Nov 12, 2026
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and VenetoclaxPHASE1_PHASE2 · RECRUITING · started Feb 2, 2026ClinicalTrials.gov NCT07148180 · fetched Nov 12, 2026
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)PHASE2 · RECRUITING · started Jan 16, 2026ClinicalTrials.gov NCT07222215 · fetched Nov 12, 2026
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian CancerPHASE1 · RECRUITING · started Jan 10, 2026ClinicalTrials.gov NCT07226427 · fetched Nov 12, 2026
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerPHASE1_PHASE2 · RECRUITING · started Nov 17, 2025ClinicalTrials.gov NCT07198724 · fetched Nov 12, 2026
Circulating Tumor DNAPHASE2 · RECRUITING · started Sep 30, 2025ClinicalTrials.gov NCT06923527 · fetched Nov 12, 2026
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AMLPHASE1_PHASE2 · RECRUITING · started Feb 10, 2025ClinicalTrials.gov NCT06561152 · fetched Nov 12, 2026
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive ChemotherapyPHASE2 · ACTIVE_NOT_RECRUITING · started Jan 14, 2025ClinicalTrials.gov NCT06456463 · fetched Nov 12, 2026
A First-in-Human Study of MEN2312 in Adults With Advanced Breast CancerPHASE1 · RECRUITING · started Oct 25, 2024ClinicalTrials.gov NCT06638307 · fetched Nov 12, 2026
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrencePHASE3 · ACTIVE_NOT_RECRUITING · started Sep 27, 2024ClinicalTrials.gov NCT06492616 · fetched Nov 12, 2026
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid LeukemiaPHASE1 · WITHDRAWN · started Aug 3, 2024ClinicalTrials.gov NCT05720988 · fetched Nov 12, 2026
Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating AgentsPHASE2 · RECRUITING · started May 1, 2024ClinicalTrials.gov NCT05442216 · fetched Nov 12, 2026
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer StudyPHASE2 · ACTIVE_NOT_RECRUITING · started May 19, 2023ClinicalTrials.gov NCT05596409 · fetched Nov 12, 2026
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic FunctionPHASE1 · COMPLETED · started Mar 13, 2023ClinicalTrials.gov NCT06126575 · fetched Nov 12, 2026
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jan 24, 2023ClinicalTrials.gov NCT05563220 · fetched Nov 12, 2026
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerPHASE1_PHASE2 · RECRUITING · started Aug 31, 2022ClinicalTrials.gov NCT05386108 · fetched Nov 12, 2026
Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerPHASE3 · COMPLETED · started May 10, 2019ClinicalTrials.gov NCT03778931 · fetched Nov 12, 2026
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)PHASE1 · RECRUITING · started Jun 26, 2017ClinicalTrials.gov NCT03113643 · fetched Nov 12, 2026
A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid TumorsPHASE1 · COMPLETED · started Feb 23, 2016ClinicalTrials.gov NCT02667873 · fetched Nov 12, 2026
Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)PHASE1_PHASE2 · COMPLETED · started Feb 10, 2016ClinicalTrials.gov NCT02268253 · fetched Nov 12, 2026
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started Jan 1, 2016ClinicalTrials.gov NCT02661022 · fetched Nov 12, 2026
SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete RemissionPHASE1_PHASE2 · TERMINATED · started Feb 1, 2015ClinicalTrials.gov NCT02270463 · fetched Nov 12, 2026
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid LeukemiaPHASE1_PHASE2 · COMPLETED · started Sep 1, 2014ClinicalTrials.gov NCT02113982 · fetched Nov 12, 2026
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma MultiformePHASE1_PHASE2 · COMPLETED · started May 1, 2014ClinicalTrials.gov NCT02078648 · fetched Nov 12, 2026